Article Abstract

No paradigm changes with checkpoint inhibitor monotherapy in patients with metastatic renal cell carcinoma and brain metastases

Authors: Sergio Bracarda, Claudia Mosillo, Fabio Trippa, Federica Urbano, Ernesto Maranzano, Claudia Caserta

Abstract

The prognosis of patients with metastatic renal cell carcinoma (mRCC) is evaluated by using the International Metastatic Renal Database Consortium risk score. Although the metastatic site is not counted in the prognostic classification, brain, liver, and bone metastases are normally considered as negative prognosticators (1).